CN109071492A - 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用 - Google Patents

氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN109071492A
CN109071492A CN201780020566.2A CN201780020566A CN109071492A CN 109071492 A CN109071492 A CN 109071492A CN 201780020566 A CN201780020566 A CN 201780020566A CN 109071492 A CN109071492 A CN 109071492A
Authority
CN
China
Prior art keywords
compound represented
compound
ring
logical formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780020566.2A
Other languages
English (en)
Other versions
CN109071492B (zh
Inventor
李心
陈阳
刘涛
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202110204338.9A priority Critical patent/CN113149961B/zh
Publication of CN109071492A publication Critical patent/CN109071492A/zh
Application granted granted Critical
Publication of CN109071492B publication Critical patent/CN109071492B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

涉及氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用。具体而言，涉及一种通式(I)所示的新的氮杂双环基取代的三唑类衍生物、其制备方法及其含有该衍生物的药物组合物及其作为治疗剂，特别是作为催产素拮抗剂的用途和在制备用于治疗或预防已知或可显示抑制催产素会产生有益效应的疾病或病症的药物中的用途，其中通式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201780020566.2A 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用 Active CN109071492B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110204338.9A CN113149961B (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611233476 2016-12-28
CN2016112334765 2016-12-28
PCT/CN2017/118784 WO2018121551A1 (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110204338.9A Division CN113149961B (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN109071492A true CN109071492A (zh) 2018-12-21
CN109071492B CN109071492B (zh) 2021-02-26

Family

ID=62710083

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780020566.2A Active CN109071492B (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用
CN202110204338.9A Active CN113149961B (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110204338.9A Active CN113149961B (zh) 2016-12-28 2017-12-27 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用

Country Status (9)

Country Link
US (1) US20210040073A1 (zh)
EP (1) EP3564231A4 (zh)
JP (1) JP2020504109A (zh)
CN (2) CN109071492B (zh)
AU (1) AU2017389819B2 (zh)
CA (1) CA3047641A1 (zh)
MX (1) MX2019007360A (zh)
TW (1) TW201823231A (zh)
WO (1) WO2018121551A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004250A (zh) * 2019-12-19 2021-06-22 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI711612B (zh) * 2018-06-27 2020-12-01 大陸商江蘇恒瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物的可藥用鹽、晶型及製備方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092731A1 (en) * 2005-03-04 2006-09-08 Pfizer Limted 1, 2, 4-triazole derivatives and their use as oxytocin antagonists
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CN101107243A (zh) * 2005-01-20 2008-01-16 辉瑞有限公司 作为催产素拮抗剂的取代三唑衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
CA2539297C (en) 2003-09-22 2010-07-20 Alan Daniel Brown Substituted triazole derivatives as oxytocin antagonists
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2602383A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2631003T3 (es) 2006-10-19 2017-08-25 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
CN102372701A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用
AU2015267909B2 (en) 2014-05-28 2018-03-22 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107243A (zh) * 2005-01-20 2008-01-16 辉瑞有限公司 作为催产素拮抗剂的取代三唑衍生物
WO2006092731A1 (en) * 2005-03-04 2006-09-08 Pfizer Limted 1, 2, 4-triazole derivatives and their use as oxytocin antagonists
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BROWN,ALAN等: "《Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.》", 《BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004250A (zh) * 2019-12-19 2021-06-22 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Also Published As

Publication number Publication date
EP3564231A1 (en) 2019-11-06
JP2020504109A (ja) 2020-02-06
CN109071492B (zh) 2021-02-26
CN113149961A (zh) 2021-07-23
CN113149961B (zh) 2022-11-22
WO2018121551A1 (zh) 2018-07-05
AU2017389819A1 (en) 2019-06-20
AU2017389819B2 (en) 2021-05-27
CA3047641A1 (en) 2018-07-05
TW201823231A (zh) 2018-07-01
EP3564231A4 (en) 2020-08-12
US20210040073A1 (en) 2021-02-11
MX2019007360A (es) 2019-08-16

Similar Documents

Publication Publication Date Title
RU2717577C2 (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP7351851B2 (ja) レチノイド関連オルファン受容体ガンマ（ＲＯＲγ）のモジュレーターとしてのベンジイミダゾール誘導体およびそれらの医薬品用途
JP2004502642A (ja) カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
CN114805462A (zh) 一种甾族类衍生物调节剂及其制备方法和应用
CN108290926A (zh) 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
TWI701251B (zh) 吡唑并[1,5-a][1,3,5]三-2-胺類衍生物、其製備方法及其在醫藥上的應用
CN107531679A (zh) 芳香酰胺类衍生物、其制备方法及其在医药上的应用
CN106518768B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的应用
WO2018113694A1 (zh) 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用
TW201536787A (zh) 吡唑並嘧啶酮類或吡咯並三嗪酮類衍生物、其製備方法及其在醫藥上的應用
CN109952298A (zh) 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
CN109071492A (zh) 氮杂双环基取代的三唑类衍生物、其制备方法及其在医药上的应用
WO2020221272A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
FR2930249A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CN109963836A (zh) 氘原子取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2018214862A1 (zh) 螺环甲酰胺类衍生物、其制备方法及其在医药上的应用
CN109485595B (zh) 亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
TW201623275A (zh) 噻吩並環烷基或噻吩並雜環基類衍生物、其製備方法及其在醫藥上的應用
CN108689996B (zh) 氮杂环丁基甲酰胺类衍生物、其制备方法及其在医药上的应用
CN109305969A (zh) 哌嗪-2,5-二酮类衍生物、其制备方法及其在医药上的应用
CN117229284B (zh) 三环稠杂环类化合物、其制备方法及其在医药上的应用
WO2022214009A1 (zh) 一种高活性的hpk1激酶抑制剂
TW202328116A (zh) 含芳環類生物拮抗劑、其製備方法及應用
CN118084629A (zh) 苯乙烯类化合物、其制备方法及其在医药上的应用
US20100029599A1 (en) Indolylamides as modulators of the EP2 receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant